Meeting ReportOral - PhysicianPharm
Safety and efficacy of radioligand therapy with 177lutetium-PSMA-617 within 3 months after 223Radium-dichloride
Justus Baumgarten, Daniel Groener, Christina Nguyen Ngoc, Nicolai Mader, Karen Davis, Philipp Mandel, Nikolaos Tselis, Christian Happel, Frank Gruenwald and Amir Sabet
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 16;
Justus Baumgarten
1Nuclear Medicine University Hospital Frankfurt Frankfurt Germany
Daniel Groener
1Nuclear Medicine University Hospital Frankfurt Frankfurt Germany
Christina Nguyen Ngoc
1Nuclear Medicine University Hospital Frankfurt Frankfurt Germany
Nicolai Mader
1Nuclear Medicine University Hospital Frankfurt Frankfurt Germany
Karen Davis
1Nuclear Medicine University Hospital Frankfurt Frankfurt Germany
Philipp Mandel
2Urology University Hospital Frankfurt Frankfurt Germany
Nikolaos Tselis
3Radiooncology University Hospital Frankfurt Frankfurt Germany
Christian Happel
1Nuclear Medicine University Hospital Frankfurt Frankfurt Germany
Frank Gruenwald
1Nuclear Medicine University Hospital Frankfurt Frankfurt Germany
Amir Sabet
1Nuclear Medicine University Hospital Frankfurt Frankfurt Germany
In this issue
Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
Safety and efficacy of radioligand therapy with 177lutetium-PSMA-617 within 3 months after 223Radium-dichloride
Justus Baumgarten, Daniel Groener, Christina Nguyen Ngoc, Nicolai Mader, Karen Davis, Philipp Mandel, Nikolaos Tselis, Christian Happel, Frank Gruenwald, Amir Sabet
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 16;
Safety and efficacy of radioligand therapy with 177lutetium-PSMA-617 within 3 months after 223Radium-dichloride
Justus Baumgarten, Daniel Groener, Christina Nguyen Ngoc, Nicolai Mader, Karen Davis, Philipp Mandel, Nikolaos Tselis, Christian Happel, Frank Gruenwald, Amir Sabet
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 16;
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.